These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 31268629)

  • 1. Resolute zotarolimus-eluting stent in ST-elevation myocardial infarction (resolute-STEMI): A prespecified prospective register from the DAPT-STEMI trial.
    Postma W; Fabris E; Van der Ent M; Hermanides R; Buszman P; Von Birgelen C C; Cook S; Wedel H; De Luca G; Delewi R; Zijlstra F; Kedhi E
    Catheter Cardiovasc Interv; 2020 Mar; 95(4):706-710. PubMed ID: 31268629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial.
    Kirtane AJ; Yeung AC; Ball M; Carr J; O'Shaughnessy C; Mauri L; Liu M; Leon MB
    Catheter Cardiovasc Interv; 2020 May; 95(6):1067-1073. PubMed ID: 31301219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
    Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
    JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
    Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial.
    Kim SH; Kang SH; Lee JM; Chung WY; Park JJ; Yoon CH; Suh JW; Cho YS; Doh JH; Cho JM; Bae JW; Youn TJ; Chae IH
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):1399-1406. PubMed ID: 31859438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
    Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thin, Very Thin, or Ultrathin Strut Biodegradable or Durable Polymer-Coated Drug-Eluting Stents: 3-Year Outcomes of BIO-RESORT.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Danse PW; Schotborgh CE; Scholte M; van Houwelingen KG; Stoel MG; Hartmann M; Tjon Joe Gin RM; Somi S; Linssen GCM; Kok MM; von Birgelen C
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1650-1660. PubMed ID: 31422087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
    JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiographic and clinical performance of polymer-free biolimus-eluting stent in patients with ST-segment elevation acute myocardial infarction in a metropolitan public hospital: The BESAMI MUCHO study.
    Sgueglia GA; D'Errico F; Gioffrè G; De Santis A; Summaria F; Piccioni F; Gaspardone A
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):851-858. PubMed ID: 28766881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
    JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: Results from the Korea Acute Myocardial infarction Registry (KAMIR).
    Kim Y; Oh SS; Jeong MH; Ahn Y; Kim JH; Hong YJ; Sim DS; Kim MC; Kim HS; Yun KH; Oh SK; Kim CJ; Cho MC
    Cardiol J; 2019; 26(5):469-476. PubMed ID: 29745969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
    Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
    Trials; 2013 Nov; 14():398. PubMed ID: 24257456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.